BlueSphere Bio was founded to deploy its novel TCXpress technology to unlock the potential of personalized T cell therapy for the treatment of cancer by harnessing the unique specificity of each patient’s own T cells for the particular molecular fingerprint of each patient’s own cancer.
Our trailblazing, proprietary TCXpress platform is an elegant, rapid approach that exploits the patient’s own immune defenses to attack their cancer specifically, and is designed to leave normal tissues untouched, thereby reducing harmful side effects.
The TCXpress platform and our implementation of it will allow us to deliver rapid, personalized T cell treatments for a variety of cancer indications.
Contact Us
CEO
Read Bio
Co-Founder and Chief Scientific Officer
Read Bio
Co-Founder and Scientific Advisory Board Chairman
Read Bio
Chief Medical Officer
Read Bio
Board Member
Read Bio
Board Member
Read Bio
Co-Founder and Vice President of Research and Development
Read Bio
Scientific Advisory Board
Read Bio
Scientific Advisory Board
Read Bio
Scientific Advisory Board
Read Bio
Scientific Advisory Board
Read Bio
Vice President of Product Development
Read Bio
Board Member
Read Bio
August 26, 2020
July 22, 2020
BlueSphere Bio has appointed a veteran drug development leader, Michael Geffner, M.D., M.B.A., as the company’s first chief medical officer.